AMG 404 in Patients With Advanced Solid Tumors

  • STATUS
    Recruiting
  • End date
    Jul 25, 2025
  • participants needed
    275
  • sponsor
    Amgen
Updated on 20 January 2022

Summary

To evaluate the safety and tolerability of AMG 404, a monoclonal antibody that binds to PD-1 and inhibits its engagement with ligands, in patients with advanced solid tumors.

Details
Condition Advanced Solid Tumors
Treatment AMG 404
Clinical Study IdentifierNCT03853109
SponsorAmgen
Last Modified on20 January 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Subject has provided informed consent prior to initiation of any study specific activities/procedures
Age greater than or equal to 18 years old at the time of signing informed consent
Life expectancy of greater than 3 months, in the opinion of the investigator
Subject must have histologically or cytologically confirmed metastatic or locally advanced solid tumors not amenable to curative treatment with surgery or radiation
At least 1 measurable as defined by modified RECIST 1.1 which has not undergone biopsy within 3 months of the screening scan. This lesion cannot be biopsied at any time during the study. Note: if there is only one lesion available for biopsy and radiographic assessment, it may be permitted to be biopsied after discussion with sponsor
Subjects with treated brain metastases are eligible provided they meet the following criteria: Definitive therapy was completed at least 2 weeks prior to enrollment. No evidence of radiographic CNS progression or CNS disease following definitive therapy and by the time of study screening. Patients manifesting progression in lesions previously treated with stereotactic radiosurgery may still be eligible if pseudoprogression can be demonstrated by appropriate means and after discussion with the medical monitor
Any CNS disease is asymptomatic, any neurologic symptoms due to CNS disease have returned to baseline or are deemed irreversible, the patient is off steroids for at least 7 days (physiologic doses of steroids are permitted), and the patient is off or on stable doses of anti-epileptic drugs for malignant CNS disease
Eastern Cooperative Oncology Group (ECOG) Performance Status of less than or equal to 2\
Hematologic function, as follows without growth factor support within 2 weeks prior to study day 1: Absolute neutrophil count (ANC) greater than or equal to 1.0 x 10E9/L; Platelet count greater than or equal to 75 x 10E9/L; Hemoglobin greater than or equal to 9 g/dL (90 g/L)
Adequate renal laboratory assessments, as follows: Estimated glomerular filtration rate based on MDRD (Modification of Diet in Renal Disease) calculation . 60 ml/min/1.73 m^2 for Cohorts 1, 2, 4 and 5
Estimated glomerular filtration rate based on MDRD (Modification of Diet in Renal Disease)
calculation >= 45 ml/min/1.73 m^2 for Cohorts 3, 6, 7, 8 and 9
Hepatic function, as follows: Total bilirubin less than or equal to 1.5 x ULN or less
than or equal to 3 x ULN for subjects with liver metastasis; AST less than or equal to
x ULN or less than or equal to' 5 x ULN for subjects with liver metastasis; ALT less
than or equal to 3 x ULN or less than or equal to 5 x ULN for subjects with liver
metastasis; Alkaline phosphatase less than or equal to 2.5 x ULN or less than or equal
to 5 x ULN for subjects with liver metastasis (Note: elevated alkaline phosphatase is
acceptable if it is due to non-hepatic associated pathology [eg, bone disease])
Cohort 5 only: Subject is a resident in China, Taiwan, or Hong Kong
Subjects enrolled to Cohorts 7-9 must submit tumor tissue sample. Fresh tumor biopsies
may be performed if subject has a readily accessible tumor lesion and who consent to
the biopsies. If fresh biopsies cannot be obtained, archival tumor samples are
acceptable. Prior to enrollment it is required to determine that there is enough tumor
tissue available to be sent to the central laboratory: Cohorts 7 and 9: Archival
tissue collected up to 12 months prior to screening date is permitted. Biopsies
collected between 12-18 months prior to screening are allowed upon discussion with the
medical monitor. Subjects with EBV associated nasopharyngeal carcinoma may submit
biopsy with EBV test results from within 36 months prior to screening; Cohort 8
Archival tissue with MSI-high/dMMR test results collected up to 36 months prior to
screening is permitted

Exclusion Criteria

History of solid organ transplantation
Major surgery within 28 days of study day 1
Live vaccine therapy within 4 weeks prior to study drug administration
Positive/Non-negative test for Human Immunodeficiency Virus (HIV)
Subject currently has an active infection requiring systemic therapy
Disease Related. Primary brain tumor, untreated or symptomatic brain metastases and
leptomeningeal disease (exception: benign asymptomatic tumors are permitted)
Other Medical Conditions. History of other malignancy within the past 2 years, with
the following exception[s]: Malignancy treated with curative intent and with no known
active disease present for greater than or equal to 2 years before enrollment and felt
to be at low risk for recurrence by the treating physician. Adequately treated
non-melanoma skin cancer or lentigo maligna without evidence of disease. Adequately
treated cervical carcinoma in situ without evidence of disease. Adequately treated
breast ductal carcinoma in situ without evidence of disease. Prostatic intraepithelial
neoplasia without evidence of prostate cancer. Adequately treated urothelial papillary
noninvasive carcinoma or carcinoma in situ. Other malignancies which do not require
systemic therapy, may be considered upon discussion with the medical monitor
Prior/Concomitant Therapy: Prior treatment with anti-programmed death 1 (PD-1)
anti-PD-L1, CTLA-4 or other checkpoint inhibitor drugs
Anti-tumor therapy (radiotherapy, chemotherapy, antibody therapy, molecular targeted
therapy, or investigational agent) within 21 days prior to study day 1. Note
Palliative radiotherapy is permitted
Current treatment or within 14 days of day 1 with immunosuppressive corticosteroid
defined as greater than 10 mg prednisone daily or equivalent. Corticosteroids with no
or minimal systemic effect (such as topical or inhalation) are permitted. Note
Corticosteroids > 10 mg prednisone used for management of contrast allergy for study
scans is allowed
Prior/Concurrent Clinical Study Experience: Currently receiving treatment in another
investigational device or drug study, or less than 21 days prior to study day 1 since
ending treatment on another investigational device or drug study(ies)
Diagnostic Assessments: Evidence of interstitial lung disease or active
non-infectious pneumonitis
History of any immune-related colitis. Infectious colitis is allowed if evidence of
adequate treatment and clinical recovery exists and at least 3 months interval
observed since diagnosis of colitis
History of allergic reactions or acute hypersensitivity reaction to antibody
therapies
Has known active Hepatitis B (eg, hepatitis B antigen [HBsAg] reactive) or Hepatitis C
(eg, HCV RNA [qualitative] is detected)
Active or history of any autoimmune disease or immunodeficiencies. Subjects with Type
I diabetes, vitiligo, psoriasis, hypo- or hyper- thyroid disease not requiring
immunosuppressive treatment are permitted
Myocardial infarction within 6 months of study day 1, symptomatic congestive heart
failure (New York Heart Association greater than class II), unstable angina, or
cardiac arrhythmia requiring antiarrhythmic medication
Unresolved toxicities from prior anti-tumor therapy, defined as not having resolved to
Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grade 1, or are
stable and well controlled with minimal, local, or non-invasive intervention AND there
is agreement to allow by both the investigator and the Amgen Medical Monitor
Other Exclusions: Males and females of reproductive potential who are unwilling to
practice highly effective methods of birth control while on study through 6 months
(females) and 8 months (males) after receiving the last dose of AMG 404
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note